UK Markets close in 6 hrs 6 mins

Pigmentation Disorders Treatment Market to Reach $8.3 Billion by 2027

ReportLinker
·26-min read

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 9. - Influencer Pool: 927. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pigmentation Disorders Treatment Industry" - https://www.reportlinker.com/p06044794/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Pigmentation Disorders Treatment Market to Reach $8.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Pigmentation Disorders Treatment estimated at US$5.7 Billion in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at a CAGR of 5.7% over the analysis period 2020-2027. Topical Drugs, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Laser Therapy segment is readjusted to a revised 5.3% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 8.7% CAGR
- The Pigmentation Disorders Treatment market in the U.S. is estimated at US$1.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 8.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.
- Chemical Peels Segment to Record 5.7% CAGR
- In the global Chemical Peels segment, USA, Canada, Japan, China and Europe will drive the 5.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$768.2 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.1 Billion by the year 2027, while Latin America will expand at a 6.9% CAGR through the analysis period.

- Select Competitors (Total 41 Featured) -

  • Allergan PLC

  • Bayer AG

  • Epipharm AG

  • Galderma SA

  • Obagi Cosmeceuticals LLC (Obagi Medical)

  • Pierre Fabre SA

  • RXi Pharmaceuticals Corporation

  • SkinCeuticals

  • Vivier Pharma, Inc.




Read the full report: https://www.reportlinker.com/p06044794/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Pigmentation
Disorders Treatment by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Pigmentation Disorders
Treatment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Pigmentation Disorders
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2020 & 2027

Table 4: World Current & Future Analysis for Topical Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Topical Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Topical Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Laser Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Laser Therapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Laser Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Chemical Peels by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Chemical Peels by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Chemical Peels by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Phototherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Phototherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Phototherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Microdermabrasion
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Microdermabrasion by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Microdermabrasion by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Other Treatments
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Other Treatments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Other Treatments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Vitiligo by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Vitiligo by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Vitiligo by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Albinism by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Albinism by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Albinism by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Other Disease
Indications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other Disease Indications
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Other Disease
Indications by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 31: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 32: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 33: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Aesthetic Clinics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 35: World Historic Review for Aesthetic Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Aesthetic Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Dermatology
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Dermatology Centers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Dermatology Centers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 40: USA Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 43: USA Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 46: USA Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 48: USA 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

CANADA
Table 49: Canada Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 52: Canada Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 55: Canada Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

JAPAN
Table 58: Japan Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 61: Japan Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 64: Japan Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

CHINA
Table 67: China Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 70: China Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 73: China Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

EUROPE
Table 76: Europe Current & Future Analysis for Pigmentation
Disorders Treatment by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Pigmentation Disorders
Treatment by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 78: Europe 15-Year Perspective for Pigmentation Disorders
Treatment by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 82: Europe Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 85: Europe Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

FRANCE
Table 88: France Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 91: France Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: France Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 93: France 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 94: France Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 95: France Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 96: France 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

GERMANY
Table 97: Germany Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Pigmentation
Disorders Treatment by Treatment - Percentage Breakdown of
Value Sales for Topical Drugs, Laser Therapy, Chemical Peels,
Phototherapy, Microdermabrasion and Other Treatments for the
Years 2012, 2020 & 2027

Table 100: Germany Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: Germany Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Germany 15-Year Perspective for Pigmentation
Disorders Treatment by Disease Indication - Percentage
Breakdown of Value Sales for Vitiligo, Albinism and Other
Disease Indications for the Years 2012, 2020 & 2027

Table 103: Germany Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 104: Germany Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 105: Germany 15-Year Perspective for Pigmentation
Disorders Treatment by End-Use - Percentage Breakdown of Value
Sales for Hospitals, Aesthetic Clinics and Dermatology Centers
for the Years 2012, 2020 & 2027

ITALY
Table 106: Italy Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 109: Italy Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: Italy Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 111: Italy 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 112: Italy Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 113: Italy Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 114: Italy 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

UNITED KINGDOM
Table 115: UK Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Pigmentation Disorders
Treatment by Treatment - Topical Drugs, Laser Therapy, Chemical
Peels, Phototherapy, Microdermabrasion and Other Treatments
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Pigmentation Disorders
Treatment by Treatment - Percentage Breakdown of Value Sales
for Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy,
Microdermabrasion and Other Treatments for the Years 2012, 2020 &
2027

Table 118: UK Current & Future Analysis for Pigmentation
Disorders Treatment by Disease Indication - Vitiligo, Albinism
and Other Disease Indications - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 119: UK Historic Review for Pigmentation Disorders
Treatment by Disease Indication - Vitiligo, Albinism and Other
Disease Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 120: UK 15-Year Perspective for Pigmentation Disorders
Treatment by Disease Indication - Percentage Breakdown of Value
Sales for Vitiligo, Albinism and Other Disease Indications for
the Years 2012, 2020 & 2027

Table 121: UK Current & Future Analysis for Pigmentation
Disorders Treatment by End-Use - Hospitals, Aesthetic Clinics
and Dermatology Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 122: UK Historic Review for Pigmentation Disorders
Treatment by End-Use - Hospitals, Aesthetic Clinics and
Dermatology Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 123: UK 15-Year Perspective for Pigmentation Disorders
Treatment by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Aesthetic Clinics and Dermatology Centers for the
Years 2012, 2020 & 2027

SPAIN
Table 124: Spain Current & Future Analysis for Pigmentation
Disorders Treatment by Treatment - Topical Drugs, Laser
Therapy, Chemical Peels, Phototherapy, Microdermabrasion and

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06044794/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001